CRISPR Therapeutics, a biopharmaceutical company focused on creating gene-based medicines for serious diseases, and ProBioGen, a German service and technology provider, have entered a multi-year research collaboration focused on the development of novel in vivo delivery modalities for CRISPR/Cas9 leveraging ProBioGen’s existing technology and expertise.

Technical and financial details of the collaboration were not disclosed. The collaboration includes a license option for CRISPR Therapeutics upon successful completion of the research goals.
“Our CRISPR/Cas9 platform has transformative potential across a broad range of devastating, genetically-defined diseases,” said Tony Ho, M.D., executive vice president, R&D at CRISPR Therapeutics. “To ensure we deliver on this potential, we continue to seek out pioneering new technologies and capabilities in support of our programs. We look forward to working with the ProBioGen team and leveraging their expertise to enhance our research and development efforts on in vivo delivery of CRISPR/Cas9.” 

ProBioGen’s chief scientific officer, Dr Volker Sandig said, “We are glad to embark on a project with CRISPR for the joint development of novel technologies for in vivo delivery of CRISPR/Cas9. This agreement combines the ideas, know-how and experience of both companies, and we look forward to enhancing CRIPSR Therapeutics’ highly innovative approach through this collaboration.”